Literature DB >> 15269665

Neuromyotonia.

J Newsom-Davis1.   

Abstract

There is increasing evidence that autoimmunity is implicated in the pathogenesis of peripheral nerve hyperexcitability (neuromyotonia, NMT and Cramp-fasciculation syndrome C-FS ) and in Maladie de Morvan in which CNS features are also present. All three conditions can associate with thymoma, myasthenia gravis and other autoimmune disorders, and can often respond to plasma exchange. In NMT, patient's plasma or IgG can transfer the electrophysiological features to mice, and can reduce voltage-gated potassium channel currents in vitro. Antibodies to voltage-gated potassium channels can be detected in the serum of many patients who have peripheral nerve hyperexcitability, and also in those with Maladie de Morvan. These latter patients have clinical features similar to limbic encephalitis in which VGKC antibodies can also occur. Thus neuromyotonia, cramp-fasciculation syndrome and Maladie de Morvan can occur as antibody-mediated autoimmune ion channelopathies like myasthenia gravis and the Lambert-Eaton myasthenic syndrome. These discoveries should aid diagnosis and offer new approaches to treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15269665     DOI: 10.1016/s0035-3787(04)71010-3

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  2 in total

1.  Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels.

Authors:  Richard G Webster; Keith L Brain; Richard H Wilson; Jean L Grem; Angela Vincent
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

Review 2.  Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders.

Authors:  Pilar Martinez-Martinez; Peter C Molenaar; Mario Losen; Jo Stevens; Marc H De Baets; Andrei Szoke; Jerome Honnorat; Ryad Tamouza; Marion Leboyer; Jim Van Os; Bart P F Rutten
Journal:  Front Genet       Date:  2013-09-20       Impact factor: 4.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.